Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: J Clin Psychopharmacol. 2016 Jun;36(3):213–221. doi: 10.1097/JCP.0000000000000488

Fig. 2.

Fig. 2

Mean number of drug choices during maintenance on 1) Placebo naltrexone and placebo alprazolam XR (PL); 2) Naltrexone (NTX) and placebo; 3) Alprazolam XR (ALP) and placebo; and 4) Naltrexone and Alprazolam XR (NTX+ALP). Symbols represent the mean of eight (8) participants. Filled symbols indicate a significant difference from the placebo-placebo condition (i.e., the data point above the leftmost “PL” on the x-axis). ‘P’ indicates a significant difference from the corresponding methamphetamine dose under the placebo maintenance condition. ‘A’ indicates a significant difference from the corresponding methamphetamine dose under the alprazolam XR maintenance condition. ‘C’ indicates a significant difference from the corresponding methamphetamine dose under the combination of naltrexone and alprazolam XR maintenance condition. Error bars indicate 1 standard error of the mean (SEM).